Yissum - Research Development Company of the Hebrew University

Targeting Neutrophils as a Therapy for Severe COVID-19 Infection

Posted by Yissum - Research Development Company of the Hebrew UniversityResponsive · Innovative Products and Technologies · Israel

Summary of the technology

Targeting Neutrophils as a Therapy for Severe COVID-19 Infection
Project ID : 47-2020-10904

Description of the technology

COVID-19 is a new, highly infectious virus that infects the respiratory system. Severe COVID-19 infection is associated with respiratory failure which may be lethal. One of the major causes for lethal respiratory failure in critically ill COVID-19 patients, is Acute Respiratory Distress Syndrome (ARDS). ARDS is a rapidly deteriorating condition where components of the immune system react excessively and cause severe lung tissue damage. While it is clear that the COVID-19 virus is capable of initiating the ARDS cascade, this pathology is propagated by neutrophils, the most abundant subset of white blood cells. After the viral replication triggers hyper inflammatory conditions and a cytokines storm, an influx of activated neutrophils is the next step in this deleterious process.

Neutrophils, an abundant type of white blood cell in the immune system, are primarily involved in protecting the host from microbial infections and inflammatory processes. However, under extreme conditions, such as COVID-19 -induced ARDS, they play a deleterious role and cause life threatening damage to the lungs. Moreover, a study published this month shows that refractory COVID-19 patients in Wuhan, China (the epicenter of the COVID-19 outbreak) present with a significant increase in neutrophil numbers compared with recovering COVID-19 patients. This observation, together with the established role neutrophils play in ARDS, highlights neutrophils as a potential therapeutic target in complicated severe COVID-19 cases.

Over the past several years, Profs. Granot and Fridlender have been developing a neutrophil-specific drug delivery platform. The specificity of this platform provides an opportunity to deliver potentially toxic drugs to neutrophils with minimal effect on other cells in the body. Using several mouse models of disease, they have proved that this platform may be used to modulate neutrophil function in vivo. As neutrophils appear to be an attractive target in treating severe COVID-19 cases, they will study the possibility of utilizing this platform as a potential therapy for severe COVID19 patients.

This therapy will have two complementary arms: A. they will use this platform to deliver a toxic molecule to neutrophils and reduce their number without harming other components of the immune system; and B. they will deliver specific inhibitors that will limit the extent of neutrophil-induced tissue damage. To test the therapeutic potential of targeting neutrophils in this context, they will use mouse models of ARDS and mouse models of coronavirus infection. They will assess how limiting neutrophil numbers, limiting neutrophil activity, or limiting both, improves survival. Profs. Granot and Fridlender have already successfully adjusted the neutrophil-specific drug delivery platform to human neutrophils. This suggests that if their experiments in mice are successful, they could be rapidly translated into a life-saving therapy.

Project manager

Keren-Or Amar
VP, Business Development, Healthcare

Project researchers

Zvika Granot
HUJI, School of Medicine - IMRIC
Developmental Biology and Cancer Research

Related keywords

  • Biological Sciences
  • Virus, Virology / Antibiotics / Bacteriology
  • Infectious Diseases
  • Genetic Engineering / Molecular Biology
  • Stem cells and biobanks
  • Covid-19
  • covid-19

About Yissum - Research Development Company of the Hebrew University

Technology Transfer Office from Israel

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Founded in 1964 to protect and commercialize the Hebrew University’s intellectual property. Ranked among the top technology transfer companies, Yissum has registered over 8,900 patents covering 2,500 inventions; has licensed out 800 technologies and has spun-off 90 companies. Products that are based on Hebrew University technologies and were commercialized by Yissum generate today over $2 Billion in annual sales.

Send your request

By clicking "Send your request" you are signing up and accepting our Terms of Service and Privacy policy

Technology Offers on Innoget are directly posted and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.